Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Sell
39
KROS Quote, Financials, Valuation and Earnings
Last price:
$18.08
Seasonality move
:
7.2%
Day range:
$18.22 - $19.13
52-week range:
$9.12 - $22.55
Dividend yield:
0%
P/E ratio:
11.86x
P/S ratio:
3.02x
P/B ratio:
0.79x
Volume:
251.9K
Avg. volume:
447K
1-year change:
59.83%
Market cap:
$557.5M
Revenue:
$3.6M
EPS (TTM):
$1.54
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$3.7M | -$0.44 | 20.4% | -61.58% | $23.38 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
INSM
Insmed, Inc.
|
$263.9M | -$1.23 | 165.76% | -30.45% | $214.00 |
|
INVA
Innoviva, Inc.
|
$101.5M | $0.43 | 6.61% | 50.34% | $32.50 |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$153.6M | -$1.25 | 45.76% | -35.54% | $90.67 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$18.30 | $23.38 | $557.5M | 11.86x | $0.00 | 0% | 3.02x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
INSM
Insmed, Inc.
|
$162.64 | $214.00 | $34.7B | -- | $0.00 | 0% | 69.21x |
|
INVA
Innoviva, Inc.
|
$19.72 | $32.50 | $1.5B | 14.15x | $0.00 | 0% | 3.88x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$82.14 | $90.67 | $13.3B | -- | $0.00 | 0% | 13.99x |
|
MNKD
MannKind Corp.
|
$5.59 | $9.61 | $1.7B | 59.34x | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
2.42% | -1.054 | 2.71% | 28.93x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
INSM
Insmed, Inc.
|
44.07% | 2.489 | 2.43% | 4.18x |
|
INVA
Innoviva, Inc.
|
20.41% | 0.020 | 18.98% | 12.93x |
|
IONS
Ionis Pharmaceuticals, Inc.
|
76.83% | 2.510 | 19.43% | 2.51x |
|
MNKD
MannKind Corp.
|
124.56% | -0.195 | 13.7% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KROS
Keros Therapeutics, Inc.
|
$13.9M | -$15.4M | 9.66% | 9.94% | -107.87% | $3.1M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
INVA
Innoviva, Inc.
|
$75.5M | $34.6M | 10.86% | 17.06% | 31.08% | $48.6M |
|
IONS
Ionis Pharmaceuticals, Inc.
|
$151.5M | -$160.2M | -9.92% | -43.01% | -102.21% | -$138.4M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
Keros Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns KROS or FOLD?
Amicus Therapeutics, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 10.24%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About KROS or FOLD?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 27.73%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Keros Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 4 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is KROS or FOLD More Risky?
Keros Therapeutics, Inc. has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock KROS or FOLD?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or FOLD?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 11.86x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.02x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.02x 11.86x $14.3M -$7.3M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns KROS or INSM?
Insmed, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -259.95%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About KROS or INSM?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 27.73%. On the other hand Insmed, Inc. has an analysts' consensus of $214.00 which suggests that it could grow by 31.58%. Given that Insmed, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 4 0 INSMInsmed, Inc.18 1 0 -
Is KROS or INSM More Risky?
Keros Therapeutics, Inc. has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.
-
Which is a Better Dividend Stock KROS or INSM?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or INSM?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 11.86x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.02x versus 69.21x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.02x 11.86x $14.3M -$7.3M INSMInsmed, Inc.69.21x -- $142.3M -$370M
-
Which has Higher Returns KROS or INVA?
Innoviva, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 80.81%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Innoviva, Inc.'s return on equity of 17.06%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M INVAInnoviva, Inc.67.87% $1.08 $1.3B -
What do Analysts Say About KROS or INVA?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 27.73%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 64.81%. Given that Innoviva, Inc. has higher upside potential than Keros Therapeutics, Inc., analysts believe Innoviva, Inc. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 4 0 INVAInnoviva, Inc.3 0 1 -
Is KROS or INVA More Risky?
Keros Therapeutics, Inc. has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.652%.
-
Which is a Better Dividend Stock KROS or INVA?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or INVA?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Innoviva, Inc. quarterly revenues of $111.3M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 11.86x while Innoviva, Inc.'s PE ratio is 14.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.02x versus 3.88x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.02x 11.86x $14.3M -$7.3M INVAInnoviva, Inc.3.88x 14.15x $111.3M $89.9M
-
Which has Higher Returns KROS or IONS?
Ionis Pharmaceuticals, Inc. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of -82.06%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M IONSIonis Pharmaceuticals, Inc.96.67% -$0.81 $2.7B -
What do Analysts Say About KROS or IONS?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 27.73%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.67 which suggests that it could grow by 10.39%. Given that Keros Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Keros Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 4 0 IONSIonis Pharmaceuticals, Inc.10 6 0 -
Is KROS or IONS More Risky?
Keros Therapeutics, Inc. has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.
-
Which is a Better Dividend Stock KROS or IONS?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or IONS?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Keros Therapeutics, Inc.'s net income of -$7.3M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 11.86x while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.02x versus 13.99x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.02x 11.86x $14.3M -$7.3M IONSIonis Pharmaceuticals, Inc.13.99x -- $156.7M -$128.6M
-
Which has Higher Returns KROS or MNKD?
MannKind Corp. has a net margin of -51.05% compared to Keros Therapeutics, Inc.'s net margin of 9.72%. Keros Therapeutics, Inc.'s return on equity of 9.94% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital KROSKeros Therapeutics, Inc.97.23% -$0.18 $721M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About KROS or MNKD?
Keros Therapeutics, Inc. has a consensus price target of $23.38, signalling upside risk potential of 27.73%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 71.93%. Given that MannKind Corp. has higher upside potential than Keros Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than Keros Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KROSKeros Therapeutics, Inc.6 4 0 MNKDMannKind Corp.8 0 0 -
Is KROS or MNKD More Risky?
Keros Therapeutics, Inc. has a beta of 0.894, which suggesting that the stock is 10.599% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.
-
Which is a Better Dividend Stock KROS or MNKD?
Keros Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Keros Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KROS or MNKD?
Keros Therapeutics, Inc. quarterly revenues are $14.3M, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Keros Therapeutics, Inc.'s net income of -$7.3M is lower than MannKind Corp.'s net income of $8M. Notably, Keros Therapeutics, Inc.'s price-to-earnings ratio is 11.86x while MannKind Corp.'s PE ratio is 59.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Keros Therapeutics, Inc. is 3.02x versus 5.50x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KROSKeros Therapeutics, Inc.3.02x 11.86x $14.3M -$7.3M MNKDMannKind Corp.5.50x 59.34x $82.1M $8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 42x
Alerts
Sell
44
SANM alert for Jan 28
Sanmina Corp. [SANM] is up 5.45% over the past day.
Sell
16
HUM alert for Jan 28
Humana, Inc. [HUM] is down 6.24% over the past day.
Sell
21
AGYS alert for Jan 28
Agilysys, Inc. [AGYS] is down 2.51% over the past day.
